CANDEL THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
CANDEL THERAPEUTICS, INC. (CADL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 76.26 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 52.47K shares, a 1.08% decline year-over-year.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 23.80K shares, a 65.15% decline year-over-year.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 59.45K shares.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 24.43K shares, a 50.24% decline year-over-year.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 205.20K shares, a 61.71% decline from fiscal 2024.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 535.92K shares, a 58.52% decline from fiscal 2023.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 1.29M shares, a 96.15% increase from fiscal 2022.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 658.68K shares, a 4512.91% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 52.47K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 76.26K shares 10-Q · filed 2026-08-13 | 135.71K shares derived: sum of 3 quarters · filed 2026-08-13 | 160.14K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 23.80K shares 10-Q · filed 2026-05-14 | 83.25K shares derived: sum of 2 quarters · filed 2026-05-14 | 107.67K shares derived: sum of 3 quarters · filed 2026-05-14 | 160.71K shares derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | 59.45K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 83.88K shares derived: sum of 2 quarters · filed 2026-03-12 | 136.91K shares derived: sum of 3 quarters · filed 2026-03-12 | 205.20K shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 24.43K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 77.47K shares derived: sum of 2 quarters · filed 2025-11-13 | 145.75K shares 10-Q · filed 2025-11-13 | 145.75K shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | 53.04K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 121.32K shares 10-Q · filed 2025-08-14 | 121.32K shares derived: sum of 3 quarters · filed 2025-08-14 | 170.41K shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 68.28K shares 10-Q · filed 2025-05-13 | 68.28K shares derived: sum of 2 quarters · filed 2025-05-13 | 117.37K shares derived: sum of 3 quarters · filed 2025-05-13 | 129.72K shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 49.09K shares derived: sum of 2 quarters · filed 2025-03-13 | 61.43K shares derived: sum of 3 quarters · filed 2025-03-13 | 535.92K shares 10-K · filed 2025-03-13 |
| 2024-09-30 | 49.09K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 61.43K shares derived: sum of 2 quarters · filed 2024-11-14 | 535.92K shares 10-Q · filed 2024-11-14 | 954.82K shares derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | 12.35K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 486.83K shares 10-Q · filed 2024-08-13 | 905.73K shares derived: sum of 3 quarters · filed 2024-08-13 | 1.31M shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 474.48K shares 10-Q · filed 2024-05-14 | 893.38K shares derived: sum of 2 quarters · filed 2024-05-14 | 1.30M shares derived: sum of 3 quarters · filed 2024-05-14 | 1.54M shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 418.90K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 821.51K shares derived: sum of 2 quarters · filed 2024-03-28 | 1.06M shares derived: sum of 3 quarters · filed 2024-03-28 | 1.29M shares 10-K · filed 2024-03-28 |
| 2023-09-30 | 402.61K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 646.04K shares derived: sum of 2 quarters · filed 2023-11-09 | 873.10K shares 10-Q · filed 2023-11-09 | 1.47M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 243.43K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 470.49K shares 10-Q · filed 2023-08-10 | 1.07M shares derived: sum of 3 quarters · filed 2023-08-10 | 1.10M shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 227.06K shares 10-Q · filed 2023-05-11 | 826.75K shares derived: sum of 2 quarters · filed 2023-05-11 | 855.47K shares derived: sum of 3 quarters · filed 2023-05-11 | |
| 2022-12-31 | 599.68K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | 628.40K shares derived: sum of 2 quarters · filed 2023-03-30 | 658.68K shares 10-K · filed 2023-03-30 | |
| 2022-09-30 | 28.72K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 58.99K shares 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | 30.27K shares 10-Q · filed 2022-08-05 | |||
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 1.08K shares derived: sum of 2 quarters · filed 2022-03-29 | 14.28K shares 10-K · filed 2022-03-29 | |
| 2021-09-30 | 1.08K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 14.28K shares 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | 13.20K shares 10-Q · filed 2021-09-08 | |||
| 2020-12-31 | 114.99K shares 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |